118 related articles for article (PubMed ID: 20931926)
1. Skin eruption and thrombocytopaenia in a woman with glaucoma: a case report.
Santos VM; Castro RA; Lima CC; Moraes MB; Sugai TA
West Indian Med J; 2010 Jan; 59(1):102-5. PubMed ID: 20931926
[TBL] [Abstract][Full Text] [Related]
2. Lichenoid drug eruption secondary to topical timolol and dorzolamide eye-drops.
Mullins RJ; Lones R; Dutta B
Australas J Dermatol; 2004 May; 45(2):151-2. PubMed ID: 15068470
[No Abstract] [Full Text] [Related]
3. Allergic contact dermatitis from timolol and dorzolamide eye drops.
Kalavala M; Statham BN
Contact Dermatitis; 2006 Jun; 54(6):345. PubMed ID: 16787459
[No Abstract] [Full Text] [Related]
4. Efficacy and tolerability of preservative-free eye drops containing a fixed combination of dorzolamide and timolol in glaucoma patients.
Renieri G; Führer K; Scheithe K; Lorenz K; Pfeiffer N; Thieme H
J Ocul Pharmacol Ther; 2010 Dec; 26(6):597-603. PubMed ID: 20977366
[TBL] [Abstract][Full Text] [Related]
5. [Raynaud's phenomenon secondary to anti-glaucoma eye drops].
Bugarín-González R; Portela-Romero M; Maceira-Rozas MC; López-Vázquez P; Bugarín-Diz C
Semergen; 2017; 43(4):e49-e50. PubMed ID: 27717655
[No Abstract] [Full Text] [Related]
6. Toxic epidermal necrolysis secondary to timolol, dorzolamide, and latanoprost eyedrops.
Flórez A; Rosón E; Conde A; González B; García-Doval I; de la Torre C; Cruces M
J Am Acad Dermatol; 2005 Nov; 53(5):909-11. PubMed ID: 16243161
[No Abstract] [Full Text] [Related]
7. A randomized trial assessing dorzolamide in patients with glaucoma who are younger than 6 years.
Ott EZ; Mills MD; Arango S; Getson AJ; Assaid CA; Adamsons IA
Arch Ophthalmol; 2005 Sep; 123(9):1177-86. PubMed ID: 16157797
[TBL] [Abstract][Full Text] [Related]
8. An eight-week, multicentric, randomized, interventional, open-label, phase 4, parallel comparison of the efficacy and tolerability of the fixed combination of timolol maleate 0.5%/brimonidine tartrate 0.2% versus fixed combination of timolol maleate 0.5%/dorzolamide 2% in patients with elevated intraocular pressure.
Hatanaka M; Grigera DE; Barbosa WL; Jordao M; Susanna R
J Glaucoma; 2008 Dec; 17(8):674-9. PubMed ID: 19092465
[TBL] [Abstract][Full Text] [Related]
9. Update in glaucoma: the new pharmacotherapies. Dorzolamide hydrochloride.
Gould LF
Can J Ophthalmol; 1998 Aug; 33(5):253-4; discussion 257-8. PubMed ID: 9740951
[No Abstract] [Full Text] [Related]
10. Fixed topical combinations in glaucomatous patients and ocular discomfort.
Nebbioso M; Evangelista M; Librando A; Di Blasio D; Pescosolido N
Expert Opin Pharmacother; 2012 Sep; 13(13):1829-35. PubMed ID: 22770575
[TBL] [Abstract][Full Text] [Related]
11. Accelerated idioventricular rhythm associated to ophthalmic timolol/dorzolamide solution.
Attanasio A; Baglio S; Quatrana M; Bartorelli L
Int J Cardiol; 2004 Jun; 95(2-3):343-5. PubMed ID: 15193844
[No Abstract] [Full Text] [Related]
12. Fixed-combination brimonidine/timolol as adjunctive therapy to a prostaglandin analog: a 3-month, open-label, replacement study in glaucoma patients.
Nguyen QH; Earl M
J Ocul Pharmacol Ther; 2009 Dec; 25(6):541-4. PubMed ID: 20028261
[TBL] [Abstract][Full Text] [Related]
13. Three-month, randomized, parallel-group comparison of brimonidine-timolol versus dorzolamide-timolol fixed-combination therapy.
Nixon DR; Yan DB; Chartrand JP; Piemontesi RL; Simonyi S; Hollander DA
Curr Med Res Opin; 2009 Jul; 25(7):1645-53. PubMed ID: 19476406
[TBL] [Abstract][Full Text] [Related]
14. Bimatoprost versus timolol and dorzolamide.
Tressler CS
Ophthalmology; 2005 Feb; 112(2):357-8; author reply 358-9. PubMed ID: 15691575
[No Abstract] [Full Text] [Related]
15. Comparison of latanoprost monotherapy and combined therapy of 0.5% timolol and 1% dorzolamide in chronic primary angle-closure glaucoma (CACG) in Japanese patients.
Sakai H; Shinjyo S; Nakamura Y; Nakamura Y; Ishikawa S; Sawaguchi S
J Ocul Pharmacol Ther; 2005 Dec; 21(6):483-9. PubMed ID: 16386090
[TBL] [Abstract][Full Text] [Related]
16. Contact dermatitis to topical drugs for glaucoma.
Holdiness MR
Am J Contact Dermat; 2001 Dec; 12(4):217-9. PubMed ID: 11753897
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and Safety of Glaucoma Patients' Switch from a 2% Dorzolamide/0.5% Timolol Fixed-Combination Brand-Name Drug to Its Generic Counterpart.
Kim YI; Kim JH; Lee TY; Lee KW
J Ocul Pharmacol Ther; 2015; 31(6):335-9. PubMed ID: 26133057
[TBL] [Abstract][Full Text] [Related]
18. Contact allergy to dorzolamide eyedrops.
Aalto-Korte K
Contact Dermatitis; 1998 Oct; 39(4):206. PubMed ID: 9817238
[No Abstract] [Full Text] [Related]
19. Ocular comfort of combination glaucoma therapies: brimonidine 0.2%/timolol 0.5% compared with dorzolamide 2%/timolol 0.5%.
Chan K; Testa M; McCluskey P
J Ocul Pharmacol Ther; 2007 Aug; 23(4):372-6. PubMed ID: 17803436
[TBL] [Abstract][Full Text] [Related]
20. Effects of dorzolamide 2% added to timolol maleate 0.5% on intraocular pressure, retrobulbar blood flow, and the progression of visual field damage in patients with primary open-angle glaucoma: a single-center, 4-year, open-label study.
Martínez A; Sánchez M
Clin Ther; 2008 Jun; 30(6):1120-34. PubMed ID: 18640468
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
